Switch theme
Sign up to access all valuation multiples
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
2009
n/a
LTM Revenue n/a
LTM EBITDA n/a
$738M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Chengdu Easton has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Chengdu Easton achieved revenue of $154M and an EBITDA of $43.9M.
Chengdu Easton expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Chengdu Easton valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $154M | n/a | XXX | XXX | XXX |
| Gross Profit | $121M | $134M | XXX | XXX | XXX |
| Gross Margin | 79% | NaN% | XXX | XXX | XXX |
| EBITDA | $43.9M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 28% | NaN% | XXX | XXX | XXX |
| Net Profit | $32.0M | $34.0M | XXX | XXX | XXX |
| Net Margin | 21% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Chengdu Easton's stock price is CNY 37 (or $5).
Chengdu Easton has current market cap of CNY 6.6B (or $909M), and EV of CNY 5.4B (or $738M).
See Chengdu Easton trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $738M | $909M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Chengdu Easton has market cap of $909M and EV of $738M.
Chengdu Easton's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Chengdu Easton's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Chengdu Easton and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $738M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpChengdu Easton's NTM/LTM revenue growth is n/a
Chengdu Easton's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Chengdu Easton's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Chengdu Easton's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Chengdu Easton and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 29% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 61% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chengdu Easton acquired XXX companies to date.
Last acquisition by Chengdu Easton was XXXXXXXX, XXXXX XXXXX XXXXXX . Chengdu Easton acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Chengdu Easton founded? | Chengdu Easton was founded in 2009. |
| Where is Chengdu Easton headquartered? | Chengdu Easton is headquartered in China. |
| Is Chengdu Easton publicy listed? | Yes, Chengdu Easton is a public company listed on SHG. |
| What is the stock symbol of Chengdu Easton? | Chengdu Easton trades under 688513 ticker. |
| When did Chengdu Easton go public? | Chengdu Easton went public in 2020. |
| Who are competitors of Chengdu Easton? | Similar companies to Chengdu Easton include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Chengdu Easton? | Chengdu Easton's current market cap is $909M |
| Is Chengdu Easton profitable? | Yes, Chengdu Easton is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
